Somatodendritic accumulation of Tau in Alzheimer's disease is promoted by Fyn‐mediated local protein translation
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769 · cited 1×
“Here, oligomeric A b (A b o) is believed to be a major neurotoxic species, causing synaptic dysfunction and neurodegeneration by a so far incompletely understood mechanism (Lesne et al , 2006; Shankar et al , 2008; Walsh et al , 2002).”
RetractedLarson, M., Sherman, M. A., Amar, F., Nuvolone, M., Schneider, J. A., Bennett, D. A., Aguzzi, A., & Lesné, S. E. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1858-12.2012 · Cited by 277 · cited 4×
“A role for Fyn in mediating A b o toxicity is further supported by studies in cultured neurons (Larson et al , 2012; Um et al , 2013, 2012).”
InfluentialRetractedWalsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291 · cited 1×
“Here, oligomeric A b (A b o) is believed to be a major neurotoxic species, causing synaptic dysfunction and neurodegeneration by a so far incompletely understood mechanism (Lesne et al , 2006; Shankar et al , 2008; Walsh et al , 2002).”
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685 · cited 1×
“Here, oligomeric A b (A b o) is believed to be a major neurotoxic species, causing synaptic dysfunction and neurodegeneration by a so far incompletely understood mechanism (Lesne et al , 2006; Shankar et al , 2008; Walsh et al , 2002).”
Bloom (2014) · doi:10.1001/jamaneurol.2013.5847 · Cited by 2,194 · cited 1×
“A large number of studies have addressed the link between these lesions, placing A b upstream of Tau in a patho-cascade (Bloom, 2014; Frandemiche et al , 2014; Jin et al , 2011; Pooler et al , 2015).”
Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models
Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, H., Chieng, B. C., Christie, M. J., Napier, I. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.036 · Cited by 1,821 · cited 3×
“Fyn has also been shown to be targeted to dendritic spines by Tau, a process that is facilitated by the interaction of Tau with the SH3 domain of Fyn, and of tyrosine-phosphorylated Tau with the SH2 domain of Fyn (Ittner et al , 2010; Lee et al , 2004; Usardi et al , 2011).”
Self-citationTwo amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K.-H., Mistl, C., Rothacher, S., Ledermann, B., Bürki, K., Frey, P., Paganetti, P. A., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13287 · Cited by 1,507 · cited 1×
“…mice (Stein et al , 1992), Fyn transgenic mice (FynCA Tg) expressing a constitutively active Y531F mutant form of human Fyn (Xia & Go¨tz, 2014), and APP23 mice expressing the human APP transgene containing the Swedish mutation (KM670/671NL) (Sturchler-Pierrat et al , 1997) were used in this study.”
In vitro characterization of conditions for amyloid-β peptide oligomerization and fibrillogenesis
Stine, W. B., Dahlgren, K. N., Krafft, G. A., & LaDu, M. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210207200 · Cited by 1,015 · cited 1×
“A b peptides were mixed thoroughly with cold F12 medium at a final concentration of 100 l M and then incubated at 4 ° C for 24 h to allow oligomerization or incubated at room temperature for 7 days to allow fibrillization (Stine et al , 2003).”
Morris, M., Maeda, S., Vossel, K., & Mucke, L. (2011) · Neuron · doi:10.1016/j.neuron.2011.04.009 · Cited by 899 · cited 1×
“This is not surprising, as Tau is known to exert such a function and interact with a range of different proteins (Klein et al , 2002; Sharma et al , 2007; Morris et al , 2011).”
Jin, M., Shepardson, N., Yang, T., Chen, G., Walsh, D., & Selkoe, D. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017033108 · Cited by 876 · cited 1×
“A large number of studies have addressed the link between these lesions, placing A b upstream of Tau in a patho-cascade (Bloom, 2014; Frandemiche et al , 2014; Jin et al , 2011; Pooler et al , 2015).”
Cited by
Tau protein liquid–liquid phase separation can initiate tau aggregation
Wegmann, S., Eftekharzadeh, B., Tepper, K., Zoltowska, K. M., Bennett, R. E., Dujardin, S., Laskowski, P. R., MacKenzie, D., Kamath, T., Commins, C., et al. (2018) · The EMBO Journal · doi:10.15252/embj.201798049 · Cited by 1,102
Local translation in neurons: visualization and function
Holt, C. E., Martin, K. C., & Schuman, E. M. (2019) · Nature Structural & Molecular Biology · doi:10.1038/s41594-019-0263-5 · Cited by 534
Synaptic degeneration in Alzheimer disease
Tzioras, M., McGeachan, R. I., Durrant, C. S., & Spires-Jones, T. L. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-022-00749-z · Cited by 504
Rodent models for Alzheimer disease
Götz, J., Bodea, L.-G., & Goedert, M. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0054-8 · Cited by 394
Self-citationAmyloid-β and tau complexity — towards improved biomarkers and targeted therapies
Polanco, J. C., Li, C., Bodea, L.-G., Martinez-Marmol, R., Meunier, F. A., & Götz, J. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.162 · Cited by 378
Self-citationAlquezar, C., Arya, S., & Kao, A. W. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2020.595532 · Cited by 367
Dendritic Tau in Alzheimer’s Disease
Ittner, A., & Ittner, L. M. (2018) · Neuron · doi:10.1016/j.neuron.2018.06.003 · Cited by 278
Molecular Pathogenesis of the Tauopathies
Götz, J., Halliday, G., & Nisbet, R. M. (2019) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-012936 · Cited by 276
Self-citationDisease-associated tau impairs mitophagy by inhibiting Parkin translocation to mitochondria
Cummins, N., Tweedie, A., Zuryn, S., Bertran‐Gonzalez, J., & Götz, J. (2019) · The EMBO Journal · doi:10.15252/embj.201899360 · Cited by 267
Self-citationGonzález, J. F., Alcántara, A. R., Doadrio, A. L., & Sánchez-Montero, J. M. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1623201 · Cited by 98
Current Status of Clinical Trials on Tau Immunotherapies
Ji, C., & Sigurdsson, E. M. (2021) · Drugs · doi:10.1007/s40265-021-01546-6 · Cited by 96
Wu, X., Yang, Z., Zou, J., Gao, H., Shao, Z., Li, C., & Lei, P. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02179-x · Cited by 88
“…family kinase inhibitor, AZD0530) has been demonstrated to rescue spatial memory de fi cits and synaptic density loss in APP/ PS1 mice, and rescue abnormalities in tau phosphorylation and deposition in 3xTg-AD mice, 271,277,281,282 suggestive of Fyn as an attractive target for the treatment of AD.”
Self-citationGhosh, A., Mizuno, K., Tiwari, S. S., Proitsi, P., Gomez Perez-Nievas, B., Glennon, E., Martinez-Nunez, R. T., & Giese, K. P. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-00882-7 · Cited by 78
PTK2B/Pyk2 overexpression improves a mouse model of Alzheimer's disease
Giralt, A., de Pins, B., Cifuentes-Díaz, C., López-Molina, L., Farah, A. T., Tible, M., Deramecourt, V., Arold, S. T., Ginés, S., Hugon, J., et al. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2018.05.020 · Cited by 64
Pyk2 is a Novel Tau Tyrosine Kinase that is Regulated by the Tyrosine Kinase Fyn
Li, C., & Götz, J. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-180054 · Cited by 52
“To confirm this finding further, we used a constitutively active (FynCA) and a kinase-dead (FynKD) Fyn mutant, mutants we have previously used to address Fyn function [12], and found that Y402 phosphorylation of Pyk2 was Fyn activity-dependent (Fig.”
BackgroundMethodInfluentialSelf-citationRoberts, J. A., Varma, V. R., An, Y., Varma, S., Candia, J., Fantoni, G., Tiwari, V., Anerillas, C., Williamson, A., Saito, A., et al. (2021) · Science Advances · doi:10.1126/sciadv.abi8178 · Cited by 49
Koren, S. A., Galvis-Escobar, S., & Abisambra, J. F. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104939 · Cited by 49
The Role of Amyloid-Beta and Tau in the Early Pathogenesis of Alzheimer’s Disease
Yin, X., Qiu, Y., Zhao, C., Zhou, Z., Bao, J., & Qian, W. (2021) · Medical Science Monitor · doi:10.12659/msm.933084 · Cited by 48
“Since tau is more closely associated with cognitive decline than Ab in the AD brain, great efforts have been made to explore tau-focused therapeutic interventions [102], and approaches focusing on pathological tau removal have been developed.”
BackgroundLeinenga, G., Koh, W. K., & Götz, J. (2019) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2019.08.002 · Cited by 31
Self-citationReelin reverts biochemical, physiological and cognitive alterations in mouse models of Tauopathy
Rossi, D., Gruart, A., Contreras-Murillo, G., Muhaisen, A., Ávila, J., Delgado-García, J. M., Pujadas, L., & Soriano, E. (2020) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101743 · Cited by 30
Metadata
- Authors
- Li, C., & Götz, J.
- Venue
- The EMBO Journal
- Published
- 2017-09
- Volume
- 36
- Issue
- 21
- Pages
- 3120-3138
- ISSN
- 0261-4189 (ISSN-L)
- 1460-2075
- OpenAlex
- W2751201591
- Cited by
- 178
- References
- 54
- FWCI
- 12.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.